Strategic partnerships Quris AI has existing and notable collaboration momentum with Merck KGaA and a planned integration with Nortis Kidney-on-Chip technology. This indicates strong receptivity to biotech partners that seek AI-enhanced safety and efficacy predictions, presenting a sales angle focused on co-development, validation partnerships, and tiered collaboration agreements.

Clinical readiness With its first AI-based drug moving toward clinical testing and a platform positioned to predict human safety outcomes, there is a clear opportunity to target late-stage biotech firms and pharma companies seeking to de-risk clinical trials, reduce failure rates, and accelerate timelines using Bio-AI safety prediction.

Financing traction Recent seed funding rounds totaling tens of millions, including SoftBank Vision Fund 2 participation, signal investor confidence and a growing budget to scale platform capabilities and partnerships. This supports a sales strategy that aligns with expanding product scope and multi-year subcription or services deals.

Global reach Recognition as a World’s Most Innovative Company and cross-border activity between Boston and Tel Aviv indicate access to international networks, potential channel partnerships, and a broader addressable market for enterprise-level AI drug development solutions.

Industry validation Long-standing engagement with Merck and ongoing integration efforts with specialized tech (Kidney-on-Chip) underline a proven value proposition in safety and efficacy prediction. This creates a compelling case study and reference for sales pitches to other large pharma and biotech R&D teams seeking comparable outcomes.